O’Day R, et al. - Researchers conducted this prospective, single-arm, cohort study to test the effectiveness and safety of a treat-and-extend protocol of aflibercept for cystoid macular oedema (CMO) secondary to central retinal vein occlusion (CRVO). This investigation was carried out at the Royal Victorian Eye and Ear Hospital, Melbourne, Australia. Participants in the study were 20 patients with CMO secondary to CRVO. According to results, 65% of patients gained 15 or more Early Treatment of Diabetic Retinopathy Study letters at 6 months, increasing to 70.6% at 12 and 18 months. The visual results obtained in this study with a treat-and-extend protocol were similar to the pivotal aflibercept trials for CMO secondary to CRVO, which used protocols monthly and then as-needed.